(INT-0073), A Randomized Comparison of Deoxycoformycin Versus Alpha-Interferon in Previously Untreated Patients With Hairy Cell Leukemia

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

Long-term follow-up of remission duration, mortality and second malignancies in hairy cell leukemia patients treated with pentostatin

IW Flinn;KJ Kopecky;MK Foucar;D Head;J Bennett;R Hutchison;W Corbett;P Cassileth;T Habermann;H Golomb;K Rai;E Eisenhauer;F Appelbaum;B Cheson;MR Grever Blood 96(9):2981-2986

Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2'-deoxycoformycin and prediction of early relapse

MS Tallman;D Hakimian;KJ Kopecky;S Wheaton;E Wollins;K Foucar;PA Cassileth;T Haberman;M Grever;JM Rowe;LC Peterson Clinical Cancer Research 5:1665-1670

Long-term results in hairy cell leukemia (HCL) treated with pentostatin.

IW Flinn;KJ Kopecky;MK Foucar;D Head;JM Bennett;RE Hutchison;WEN Corbett;PA Cassileth;T Habermann;H Golomb;K Rai;E Eisenhauer;FR Appelbaum;BD Cheson;M Grever Blood 90(10)Suppl.1:578a(#2575)

Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An Intergroup study

M Grever;K Kopecky;MK Foucar;D Head;JM Bennett;RE Hutchison;WEN Corbett;PA Cassileth;T Habermann;H Golomb;K Rai;E Eisenhauer;F Appelbaum;BD Cheson Journal of Clinical Oncology 13(4):974-982

A randomized comparison of deoxycofomycin (DCF) versus alpha-2a interferon (IFN) in previously untreated patients with hairy cell leukemia (HCL): An NCI-sponsored intergroup study. (SWOG, ECOG, CALGB, NCIC-CTG).

M Grever;K Kopecky;D Head;P Cassileth;H Golomb;T Habermann;K Rai;E Eisenhauer;B Cheson ASCO 11:264(#868)